These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11883698)

  • 1. Technology evaluation: APC-8015, Dendreon.
    Rini BI
    Curr Opin Mol Ther; 2002 Feb; 4(1):76-9. PubMed ID: 11883698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
    Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
    Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
    Lin AM; Hershberg RM; Small EJ
    Urol Oncol; 2006; 24(5):434-41. PubMed ID: 16962496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
    Small EJ; Fratesi P; Reese DM; Strang G; Laus R; Peshwa MV; Valone FH
    J Clin Oncol; 2000 Dec; 18(23):3894-903. PubMed ID: 11099318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vaccine therapy of prostate cancer].
    Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
    Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
    Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S
    Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technology evaluation: DCVax, Northwest Biotherapeutics.
    Knutson KL
    Curr Opin Mol Ther; 2002 Aug; 4(4):403-7. PubMed ID: 12222879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell vaccines for the treatment of prostate cancer.
    Lehrfeld TJ; Lee DI
    Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
    Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
    Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DC therapy for prostate cancer.
    Swindle PW; Tepes S; Clements J
    Cytotherapy; 2004; 6(2):164-71. PubMed ID: 15203993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
    Arlen PM; Gulley JL; Tsang KY; Schlom J
    Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
    Eymard JC; Gervais A; Jarcau R; Bernard J
    Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic vaccines for prostate cancer: a review of clinical data.
    Arlen PM; Gulley JL
    Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GVAX (Cell Genesys).
    Dummer R
    Curr Opin Investig Drugs; 2001 Jun; 2(6):844-8. PubMed ID: 11572668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technology evaluation: APC-80200, Dendreon.
    Rice A; Hart D
    Curr Opin Mol Ther; 2002 Oct; 4(5):523-7. PubMed ID: 12435055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunotherapy of prostate and bladder cancer.
    Totterman TH; Loskog A; Essand M
    BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.